Selvita ($225m market cap) is an oncology focused biotechnology company. Broad oncology targeted therapeutics pipeline includes kinase inhibitor and synthetic lethality programs. Lead programs include SEL24, a first in class PIM/FLT3 kinase inhibitor in Ph 1/2 in AML (partnered with Menarini) and SEL120, a small molecule selective CDK8 inhibitor currently in IND enabling studies for leukemias, lymphomas, and solid tumors, with Ph 1/2 initiation expected in H1 2019. Earlier stage pipeline from Cancer Cell Metabolism and Immunometabolism Platform and Immuno oncology Platform.
Park Life Science
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.